PALO ALTO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced the appointment of Laura Hamill, an accomplished pharmaceutical and biotechnology executive, to its Board of Directors. Ms. Hamill brings to the Scilex board more than three decades of experience in the biopharma industry, serving most recently as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc. Prior to Gilead, she spent 18 years at Amgen Inc. in a number of leadership roles in the U.S. and internationally, concluding her time there as Senior Vice President and General Manager, with strategic oversight of Amgen’s U.S. commercial operations. During her career, Ms. Hamill has worked across a vast array of therapeutic areas, including inflammation, oncology, pain, virology and cardiovascular disease. She is a member of the boards of directors of BB Biotech, AnaptysBio, Inc., Pardes Biosciences, Y-mAbs Therapeutics, Inc., and Unchained Labs, a private company of Carlyle Group. Ms. Hamill also served on the board of director at Acceleron Pharmaceuticals, Inc. before it was acquired by Merck in 2021. Ms. Hamill holds a B.A. in business administration from the University of Arizona.
The rest is here:
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly...
Recommendation and review posted by Fredricko
